Drug intelligence / Profile preview

TQH3910

Development stage: Preclinical
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQH3910 is an orally administered small molecule drug candidate under investigation for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. The precise mechanism of action for TQH3910 has not been disclosed or remains unknown. There are currently no FDA approvals or clinical trials registered for this agent, and its development status appears to be preclinical or very early stage[1][2][3].

Beyond the preview

Go deeper on TQH3910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQH3910.

Explore the full profile